Serono maintained by Jefferies at hold

Serono SA was maintained by Jefferies & Co. analyst Adam Walsh at a hold rating with a price target on the stock of $18 per share following the supplementary biologics license application made by Biogen Idec Inc. and Elan Corp. plc for a revised label for their multiple sclerosis drug Tysabri, in competition with Serono's Rebif. In the U.S., Serono shares Tuesday were down $0.06, or 0.37%, at $16.07 on volume of 102,500 shares versus the three-month running average of 98,287.5 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.